1. Scrip
  2. >>R&D

Alphabet To AI Connect, What Favors Drug Development At Indian Institutes Of Technology

CAR-T Dream Achieved

 
• By Vibha Ravi

After starring in India’s first CAR-T treatment, the country’s Indian Institutes of Technology, or IITs, are set to expand their drug development footprint. Scrip takes a look at what the Indian equivalents of the Massachusetts Institute of Technology have going for them, including sizeable funding and alumni like Alphabet's CEO.

Building R&D Capability
Indian Institutes Of Technology Are Building R&D Capabilities In Healthcare • Source: Shutterstock

The launch of India’s first indigenous chimeric antigen receptor (CAR)-T cell therapy NexCAR19 (actalycabtagene autoleucel) last month at nearly 10% of the price of similar treatments available in the country was a truly significant moment.

Its impact on access was recognized not just by India’s president and the government, but also by Time magazine, which...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

Gilead’s Yeztugo Gets US Approval For Twice-Yearly PrEP

 
• By Alexandra Shimmings

The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.